Citations

Clear

479 citation(s) found for "Tobias, JS".

European Society of Cardiology quality indicators for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
Aktaa, Suleman , Tzeis, Stylianos , Gale, Chris P , Ackerman, Michael J. , Arbelo, Elena , Behr, Elijah R. , Crotti, Lia , Chillou, Christian de , Deneke, Thomas , Friede, Tim , Leclercq, Christophe , Merino, José Luís , Semsarian, Chris, Verstrael, Axel , Zeppenfeld, Katja , Tfelt‐Hansen, Jacob , Crotti, Lia , Zeppenfeld, Katja , de Chillou, Christian , Deneke, Thomas , Figueiredo, Márcio , Friede, Tim , Leclercq, Christophe , Merino, Jose L , Semsarian, Christopher , Zeppenfeld, Katja , Tfelt-Hansen, Jacob , Reichlin, Tobias , Crotti, Lia , Behr, Elijah Raphael , Zeppenfeld, Katja , Arbelo, Elena , d'Avila, Andre

Mayo Clinic

Europace | August 24, 2022 | Volume: 25 | Issue: 1 | Pages: 199-210

10.1093/europace/euac114 | PMID 36753478 Get It

Abstract To develop a suite of quality indicators (QIs) for the management of patients with ventricular arrhythmias (VA) and the prevention of sudden cardiac death (SCD). The Working Group comprised experts in heart rhythm management including Task Force members of the 2022 European Society of Cardiology (ESC) Clinical Practice Guidelines for the management of patients with VA and the prevention of SCD, members of the European Heart Rhythm Association, international experts, and a patient representative. We followed the ESC methodology for QI development, which involves (i) the identification of the key domains of care for the management of patients with VA and the prevention of SCD by constructing a conceptual framework of care, (ii) the development of candidate QIs by conducting a systematic review of the literature, (iii) the selection of the final set of QIs using a modified-Delphi method, and (iv) the evaluation of the feasibility of the developed QIs. We identified eight domains of care for the management of patients with VA and the prevention of SCD: (i) structural framework, (ii) screening and diagnosis, (iii) risk stratification, (iv) patient education and lifestyle modification, (v) pharmacological treatment, (vi) device therapy, (vii) catheter ablation, and (viii) outcomes, which included 17 main and 4 secondary QIs across these domains. Following a standardized methodology, we developed 21 QIs for the management of patients with VA and the prevention of SCD. The implementation of these QIs will improve the care and outcomes of patients with VA and contribute to the prevention of SCD.
Real-time Ultrasound-Guided Manual Testicular Detorsion: A Case Report
Smith, W. Ted, Midgley, S.J.E. , Kummer, Tobias , Midgley, Stephanie

Mayo Clinic

Clinical Practice and Cases in Emergency Medicine | August 23, 2022 | Volume: 6 | Issue: 3 | Pages: 248-251

10.5811/cpcem2022.6.57256 | PMID 36049193 Get It

Introduction: Acute testicular torsion is a surgical emergency due to acute testicular ischemia. Manual testicular detorsion is a testis-saving, bedside therapeutic when performed correctly and in a timely fashion. This procedure is most commonly performed blindly with pain relief as the endpoint for detorsion. However, up to one-third of patients continued to show signs of residual torsion in the operating room even using pain relief as the stopping point for the procedure. Case Report: We present a case demonstrating the utility of color Doppler ultrasound to confirm complete manual detorsion in a 14-year-old male with acute testicular torsion. The patient underwent 360-degree detorsion and had relief of pain; however, color Doppler demonstrated incomplete return of flow to the testis. After an additional 180-degree turn was made, color Doppler demonstrated complete return of normal vascular flow to the torsed testis. Conclusion: When it comes to testicular viability, timely restoration of blood flow to the testicle is of utmost importance. Manual detorsion is a non-invasive intervention that can be quickly and effectively performed at the bedside. Moreover, using color Doppler ultrasound guidance can ensure that physicians detorse in the proper direction and to completion, by providing instant visualization of restorative flow and ensuring reperfusion of the testis while awaiting definitive surgical management.
Presentation, Management, and Outcomes of Urinary Bladder Paraganglioma: Results From a Multicenter Study
Yu, Kai , Ebbehøj, Andreas , Obeid, Hiba, Vaidya, Anand , Else, Tobias , Wachtel, Heather , Main, Ailsa Maria , Søndergaard, Esben , Christensen, Louise Lehmann , Cohen, Debbie L. , Bennett, Bonita, Andersen, Marianne , Larsson, Catharina , Almeida, Madson Q. , Boorjian, Stephen A. , Ebbehøj, Andreas Ladefoged , Fishbein, Lauren , Bancos, Irina , Almeida, Madson Q , Juhlin, C. Christofer , Calissendorff, Jan , Young, William F. , Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 26, 2022 | Volume: 107 | Issue: 10 | Pages: 2811-2821

10.1210/clinem/dgac427 | PMID 35882219 Get It

Abstract Context Urinary bladder paraganglioma (UBPGL) is rare. Objective We aimed to characterize the presentation and outcomes of patients diagnosed with UBPGL. Methods We conducted a multicenter study of consecutive patients with pathologically confirmed UBPGL evaluated between 1971 and 2021. Outcomes included repeat bladder surgery, metastases, and disease-specific mortality. Results Patients (n=110 total; n=56 [51%] women) were diagnosed with UBPGL at a median age of 50 years (interquartile range [IQR], 36-61 years). Median tumor size was 2 cm (IQR, 1-4 cm). UBPGL was diagnosed prior to biopsy in only 37 (34%), and only 69 (63%) patients had evaluation for catecholamine excess. In addition to the initial bladder surgery, 26 (25%) required multiple therapies, including repeat surgery in 10 (9%). Synchronous metastases were present in 9 (8%) patients, and 24 (22%) other patients with UBPGL developed metachronous metastases at a median of 4 years (IQR, 2-10 years) after the initial diagnosis. Development of metachronous metastases was associated with younger age (hazard ratio [HR] 0.97; 95% CI, 0.94-0.99), UBPGL size (HR 1.69; 95% CI, 1.31-2.17), and a higher degree of catecholamine excess (HR 5.48; 95% CI, 1.40-21.39). Disease-specific mortality was higher in patients with synchronous metastases (HR 20.80; 95% CI, 1.30-332.91). Choice of initial surgery, genetic association, sex, or presence of muscular involvement on pathology were not associated with development of metastases or mortality. Conclusions Only a minority of patients were diagnosed before biopsy/surgery, reflecting need for better diagnostic strategies. All patients with UBPGL should have lifelong monitoring for development of recurrence and metastases.
Histopathology and Genetic Causes of Primary Aldosteronism in Young Adults
Nanba, Kazutaka , Baker, Jessica , Blinder, Amy, Bick, Nolan , Lim, Jung Soo , Wachtel, Heather , Cohen, Debbie L. , Williams, Tracy Ann , Reincke, Martín , Lyden, Melanie L. , Else, Tobias , Rainey, William E. , Wachtel, Heather , Williams, Tracy Ann , Reincke, Martin , Bancos, Irina , Else, Tobias , Rainey, William E , Nanba, Kazutaka , Liu, Chia‐Jen , Bancos, Irina , Young, William F. , Giordano, Thomas J. , Udager, Aaron M

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 2, 2022 | Volume: 107 | Issue: 9 | Pages: 2473-2482

10.1210/clinem/dgac408 | PMID 35779252 Get It

Abstract Context Due to its rare incidence, molecular features of primary aldosteronism (PA) in young adults are largely unknown. Recently developed targeted mutational analysis identified aldosterone-driver somatic mutations in aldosterone-producing lesions, including aldosterone-producing adenomas (APAs), aldosterone-producing nodules (APNs), and aldosterone-producing micronodules, formerly known as aldosterone-producing cell clusters. Objective To investigate histologic and genetic characteristics of lateralized PA in young adults. Methods Formalin-fixed, paraffin-embedded adrenal tissue sections from 74 young patients with lateralized PA (<35 years old) were used for this study. Immunohistochemistry (IHC) for aldosterone synthase (CYP11B2) was performed to define the histopathologic diagnosis. Somatic mutations in aldosterone-producing lesions were further determined by CYP11B2 IHC-guided DNA sequencing. Results Based on the CYP11B2 IHC results, histopathologic classification was made as follows: 48 APAs, 20 APNs, 2 multiple aldosterone-producing nodules (MAPN), 1 double APN, 1 APA with MAPN, and 2 nonfunctioning adenomas (NFAs). Of 45 APAs with successful sequencing, 43 (96%) had somatic mutations, with KCNJ5 mutations being the most common genetic cause of young-onset APA (35/45, 78%). Of 18 APNs with successful sequencing, all of them harbored somatic mutations, with CACNA1D mutations being the most frequent genetic alteration in young-onset APN (8/18, 44%). Multiple CYP11B2-expressing lesions in patients with MAPN showed several aldosterone-driver mutations. No somatic mutations were identified in NFAs. Conclusion APA is the most common histologic feature of lateralized PA in young adults. Somatic KCNJ5 mutations are common in APAs, whereas CACNA1D mutations are often seen in APNs in this young PA population.
Longitudinal Retinal Changes in MOGAD
Oertel, Frederike Cosima , Sotirchos, Elias S. , Zimmermann, Hanna , Motamedi, Seyedamirhosein , Specovius, Svenja , Asseyer, Eva Susanna, Chien, Claudia , Cook, Lawrence J. , Vasileiou, Eleni S. , Filippatou, Angeliki , D’Cunha, Anitha , Pittock, Sean J. , Bhatti, M. Tariq , Rommer, Paulus , Bsteh, Gabriel , Zrzavy, Tobias , Kuempfel, Tania, Aktaş, Orhan , Ringelstein, Marius , Ayzenberg, Ilya , Pakeerathan, Thivya , Knier, Benjamin , Asgari, Nasrin , Soelberg, Kerstin , Marignier, Romain , Tilikete, Caroline , Calvo, Álvaro Cobo, Villoslada, Pablo , Sánchez‐Dalmau, Bernardo , Green, Ari , Brandt, Alexander U. , Chen, John , Paul, Friedemann , Palace, Jacqueline , Chen, John J. , Asseyer, Susanna , Huda, Saif , Zimmermann, Hanna G , Vasileiou, Eleni , Calabresi, Peter A , Pandit, Lekha , Zéphir, Hélène , Pittock, S J , Bsteh, Gabriel , Zrzavy, Tobias , Kuempfel, Tania , Ringelstein, Marius , Albrecht, Philipp , Knier, Benjamin , Aly, Lilian , Marignier, Romain , Villoslada, Pablo , Brandt, Alexander U , Paul, Friedemann , Chen, John J , Sotirchos, Elias S , Oertel, Frederike C , Palace, Jacqueline , Rommer, Paulus S , Filippatou, Angeliki G , Cook, Lawrence J , Calabresi, Peter A. , Saidha, Shiv , Pandit, Lekha , Outteryck, Olivier , Flanagan, Eoin P. , Kümpfel, Tania , Martínez‐Lapiscina, Elena H. , Llufriú, Sara , Yeaman, Michael R , Smith, Terry J. , Havla, Joachim

Mayo Clinic

Annals of Neurology | June 15, 2022 | Volume: 92 | Issue: 3 | Pages: 476-485

10.1002/ana.26440 | PMID 35703428 Get It

ObjectivePatients with myelin oligodendrocyte glycoprotein antibody (MOG‐IgG)‐associated disease (MOGAD) suffer from severe optic neuritis (ON) leading to retinal neuro‐axonal loss, which can be quantified by optical coherence tomography (OCT). We assessed whether ON‐independent retinal atrophy can be detected in MOGAD.MethodsEighty patients with MOGAD and 139 healthy controls (HCs) were included. OCT data was acquired with (1) Spectralis spectral domain OCT (MOGAD: N = 66 and HCs: N = 103) and (2) Cirrus high‐definition OCT (MOGAD: N = 14 and HCs: N = 36). Macular combined ganglion cell and inner plexiform layer (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) were quantified.ResultsAt baseline, GCIPL and pRNFL were lower in MOGAD eyes with a history of ON (MOGAD‐ON) compared with MOGAD eyes without a history of ON (MOGAD‐NON) and HCs (p < 0.001). MOGAD‐NON eyes had lower GCIPL volume compared to HCs (p < 0.001) in the Spectralis, but not in the Cirrus cohort. Longitudinally (follow‐up up to 3 years), MOGAD‐ON with ON within the last 6–12 months before baseline exhibited greater pRNFL thinning than MOGAD‐ON with an ON greater than 12 months ago (p < 0.001). The overall MOGAD cohort did not exhibit faster GCIPL thinning compared with the HC cohort.InterpretationOur study suggests the absence of attack‐independent retinal damage in patients with MOGAD. Yet, ongoing neuroaxonal damage or edema resolution seems to occur for up to 12 months after ON, which is longer than what has been reported with other ON forms. These findings support that the pathomechanisms underlying optic nerve involvement and the evolution of OCT retinal changes after ON is distinct in patients with MOGAD. ANN NEUROL 2022;92:476–485
The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications
Brunklaus, Andreas , Brünger, Tobias , Feng, Tony, Lehikoinen, Anni , Panagiotakaki, Eleni , Vințan, Mihaela Adela , Symonds, Joseph D. , Andrew, James E., Delima, Sarah , Gallois, Julie, Hanrahan, Donncha, Macleod, Stewart, Marjanović, Dragan , McTague, Amy , Nuñez-Enamorado, Noemi, Pérez‐Palma, Eduardo , Perry, Μ. Scott , Pysden, Karen, Russ-Hall, Sophie , Scheffer, Ingrid E. , Sully, Krystal , Syrbe, Steffen , Vaher, Ulvi , Velayutham, Murugan, Vogt, Julie , Weiss, Shelly K. , Zuberi, Sameer M. , Lal, Dennis , Møller, Rikke S. , Mantegazza, Massimo , Symonds, Joseph , Zuberi, Sameer M , Mantegazza, Massimo , Brunklaus, Andreas , Scheffer, Ingrid E , Møller, Rikke S , Fons, Carmen , Andrew, James, Arzimanoglou, Alexis , Lesca, Gaëtan , Núñez‐Enamorado, Noemí , Wirrell, Elaine , Cestèle, Sandrine

Mayo Clinic

Brain | June 13, 2022 | Volume: 145 | Issue: 11 | Pages: 3816-3831

10.1093/brain/awac210 | PMID 35696452 Get It

Abstract Brain voltage-gated sodium channel NaV1.1 (SCN1A) loss-of-function variants cause the severe epilepsy Dravet syndrome, as well as milder phenotypes associated with genetic epilepsy with febrile seizures plus. Gain of function SCN1A variants are associated with familial hemiplegic migraine type 3. Novel SCN1A-related phenotypes have been described including early infantile developmental and epileptic encephalopathy with movement disorder, and more recently neonatal presentations with arthrogryposis. Here we describe the clinical, genetic and functional evaluation of affected individuals. Thirty-five patients were ascertained via an international collaborative network using a structured clinical questionnaire and from the literature. We performed whole-cell voltage-clamp electrophysiological recordings comparing sodium channels containing wild-type versus variant NaV1.1 subunits. Findings were related to Dravet syndrome and familial hemiplegic migraine type 3 variants. We identified three distinct clinical presentations differing by age at onset and presence of arthrogryposis and/or movement disorder. The most severely affected infants (n = 13) presented with congenital arthrogryposis, neonatal onset epilepsy in the first 3 days of life, tonic seizures and apnoeas, accompanied by a significant movement disorder and profound intellectual disability. Twenty-one patients presented later, between 2 weeks and 3 months of age, with a severe early infantile developmental and epileptic encephalopathy and a movement disorder. One patient presented after 3 months with developmental and epileptic encephalopathy only. Associated SCN1A variants cluster in regions of channel inactivation associated with gain of function, different to Dravet syndrome variants (odds ratio = 17.8; confidence interval = 5.4–69.3; P = 1.3 × 10−7). Functional studies of both epilepsy and familial hemiplegic migraine type 3 variants reveal alterations of gating properties in keeping with neuronal hyperexcitability. While epilepsy variants result in a moderate increase in action current amplitude consistent with mild gain of function, familial hemiplegic migraine type 3 variants induce a larger effect on gating properties, in particular the increase of persistent current, resulting in a large increase of action current amplitude, consistent with stronger gain of function. Clinically, 13 out of 16 (81%) gain of function variants were associated with a reduction in seizures in response to sodium channel blocker treatment (carbamazepine, oxcarbazepine, phenytoin, lamotrigine or lacosamide) without evidence of symptom exacerbation. Our study expands the spectrum of gain of function SCN1A-related epilepsy phenotypes, defines key clinical features, provides novel insights into the underlying disease mechanisms between SCN1A-related epilepsy and familial hemiplegic migraine type 3, and identifies sodium channel blockers as potentially efficacious therapies. Gain of function disease should be considered in early onset epilepsies with a pathogenic SCN1A variant and non-Dravet syndrome phenotype.
Risk of Postoperative Thromboembolism in Men Undergoing Urological Prosthetic Surgery: An Assessment of 21,413 Men
Hebert, Kevin , Matta, Rano , Horns, Joshua J. , Paudel, Niraj, Das, Rupam , Köhler, Tobias , McCormick, Benjamin J. , Hotaling, James M. , Myers, Jeremy B. , Hebert, Kevin J , McCormick, Benjamin J , Myers, Jeremy B , Pastuszak, Alexander W.

Mayo Clinic

Journal of Urology | June 10, 2022 | Volume: 208 | Issue: 4 | Pages: 878-885

10.1097/ju.0000000000002801 | PMID 35686836 Get It

Radiomics Based Classification of Pulmonary Nodules Into Adeno - and Non-Adenocarcinomas, Virtual Lung Biopsy
Al-Ghoula, F., Rajagopalan, Srinivas, Clay, RD., Peikert, Tobias, Rajagopalan, Srinivasan , Clay, Ryan , Bartholmai, Brian J.

Mayo Clinic

B30. THE QUEST FOR THE HOLY GRAIL: MODELING AND BIOMARKERS FOR NODULES AND LUNG CANCER | May 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: A5588-A5588

10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5588 Get It

The Diagnosis and Management of Recurrent Ischemic Priapism, Priapism in Sickle Cell Patients, and Non-Ischemic Priapism: An AUA/SMSNA Guideline
Bivalacqua, Trinity J. , Allen, Bryant , Brock, Gerald, Köhler, Tobias , Mulhall, John P. , Oristaglio, Jeff, Rahimi, Leila L., Rogers, Zora R. , Terlecki, Ryan , Trost, Landon , Yafi, Faysal A. , Bennett, Nelson , Broderick, Gregory A. , Chou, Roger

Mayo Clinic

Journal of Urology | May 10, 2022 | Volume: 208 | Issue: 1 | Pages: 43-52

10.1097/ju.0000000000002767 | PMID 35536142 Get It

Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1 st edition
Tassorelli, Cristina , Silberstein, Stephen D. , Szperka, Christina L. , Kurth, Tobias , Amin, Faisal Mohammad , Tassorelli, Cristina , Silberstein, Stephan D , Szperka, Christina L , Kurth, Tobias , Diener, Hans-Christoph , Schwedt, Todd J. , Pozo‐Rosich, Patricia , Lipton, Richard B. , Dodick, David W. , Ashina, Messoud , Diener, Hans‐Christoph , Terwindt, Gisela M.

Mayo Clinic

Cephalalgia | May 6, 2022 | Volume: 42 | Issue: 11-12 | Pages: 1099-1115

10.1177/03331024221099035 | PMID 35514209 Get It

Clinic-based headache registries collect data for a wide variety of purposes including delineating disease characteristics, longitudinal natural disease courses, headache management approaches, quality of care, treatment safety and effectiveness, factors that predict treatment response, health care resource utilization, clinician adherence to guidelines, and cost-effectiveness. Registry data are valuable for numerous stakeholders, including individuals with headache disorders and their caregivers, healthcare providers, scientists, healthcare systems, regulatory authorities, pharmaceutical companies, employers, and policymakers. This International Headache Society document may serve as guidance for developing clinic-based headache registries. Use of registry data requires a formal research protocol that includes: 1) research aims; 2) methods for data collection, harmonization, analysis, privacy, and protection; 3) methods for human subject protection; and 4) publication and dissemination plans. Depending upon their objectives, headache registries should include validated headache-specific questionnaires, patient reported outcome measures, data elements that are used consistently across studies (i.e., “common data elements”), and medical record data. Amongst other data types, registries may be linked to healthcare and pharmacy claims data, biospecimens, and neuroimaging data. Headache diagnoses should be made according to the International Classification of Headache Disorders diagnostic criteria. The data from well-designed headache registries can provide wide-ranging and novel insights into the characteristics, burden, and treatment of headache disorders and ultimately lead to improvements in the management of patients with headache.